Sian Morgan

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

R. Butler, G. Schiavon, R. Venkitaraman, 2022, The Lancet. Oncology.

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

R. Butler, M. Cerone, G. Middleton, 2023, British Journal of Cancer.

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

R. Butler, G. Schiavon, C. Twelves, 2022, Journal of Clinical Oncology.